Skip to main content

27.10.2024

The Impact of Standardized Training Resident on Pain Management in Patients with Advanced Lung Cancer

verfasst von: Hai-Zhen Yi, Wei Lv, Jin-Jing Chen, Zhan Lin

Erschienen in: Journal of Cancer Education

Einloggen, um Zugang zu erhalten

Abstract

This study aimed to investigate the effects of Standardized Training Resident on pharmacological interventions for pain management in patients with advanced lung cancer. A total of 84 patients with advanced lung cancer and associated pain were enrolled in the study from December 2019 to August 2023 and were divided into two groups based on their attending physician: a group managed by physician-ST Training Physicians (joint group) (n = 42) and physician-only group (usual group) (n = 42). The Brief Pain Inventory (BPI), oral morphine equivalent, and length of hospital stay. Furthermore, the Pain Management Index (PMI) was calculated. Health-related quality of life (HRQoL) was assessed at the 4-week follow-up using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). At week 4, compared to the usual group, the four BPI pain intensity categories were significantly lower in the joint group [worst pain: 4 (3–5) vs 8 (7–9); least pain: 1 (0–2) vs 3 (1–4); average pain: 2 (1–2) vs 5 (4–6); pain right now: 1.2 (0.7–1.9) vs 4 (3–5)] (all P > 0.05). The hospital stay duration was significantly reduced; for the seven pain interference categories, there were no significant improvements in the joint group. Significantly more patients achieved adequate pain control in the joint group than the usual group (p = .002). A reduction in OMEDD scores was observed for both cohorts, and the joint group’s reduction was statistically more significant (p = 0.016). There were no significant differences in HRQoL between the two groups. Standardized Training for Radiation Oncology Physicians may lead to improved pharmacological interventions and enhanced pain relief. Recognizing the importance of these trainees in the healthcare team is crucial for achieving optimal pain management outcomes.
Literatur
1.
Zurück zum Zitat Cao B, Bray F, Beltran-Sánchez H, Ginsburg O, Soneji S, Soerjomataram I (2017) Benchmarking life expectancy and cancer mortality: global comparison with cardiovascular disease 1981–2010. BMJ 357:j2765CrossRefPubMedPubMedCentral Cao B, Bray F, Beltran-Sánchez H, Ginsburg O, Soneji S, Soerjomataram I (2017) Benchmarking life expectancy and cancer mortality: global comparison with cardiovascular disease 1981–2010. BMJ 357:j2765CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424CrossRefPubMed Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424CrossRefPubMed
3.
Zurück zum Zitat Portenoy RK, Ahmed E (2014) Principles of opioid use in cancer pain. J Clin Oncol 32(16):1662–1670CrossRefPubMed Portenoy RK, Ahmed E (2014) Principles of opioid use in cancer pain. J Clin Oncol 32(16):1662–1670CrossRefPubMed
4.
Zurück zum Zitat Kwon JH (2014) Overcoming barriers in cancer pain management. J Clin Oncol 32(16):1727–1733CrossRefPubMed Kwon JH (2014) Overcoming barriers in cancer pain management. J Clin Oncol 32(16):1727–1733CrossRefPubMed
5.
6.
Zurück zum Zitat Simone CB 2nd, Vapiwala N, Hampshire MK, Metz JM (2012) Cancer patient attitudes toward analgesic usage and pain intervention. Clin J Pain 28:157–162CrossRefPubMedPubMedCentral Simone CB 2nd, Vapiwala N, Hampshire MK, Metz JM (2012) Cancer patient attitudes toward analgesic usage and pain intervention. Clin J Pain 28:157–162CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Romaszko AM, Doboszyńska A (2018) Multiple primary lung cancer: a literature review. Adv Clin Exp Med 27:725–730CrossRefPubMed Romaszko AM, Doboszyńska A (2018) Multiple primary lung cancer: a literature review. Adv Clin Exp Med 27:725–730CrossRefPubMed
8.
Zurück zum Zitat Jones GS, Baldwin DR (2018) Recent advances in the management of lung cancer. Clin Med (Lond) 18(Suppl 2):s41–s46CrossRefPubMed Jones GS, Baldwin DR (2018) Recent advances in the management of lung cancer. Clin Med (Lond) 18(Suppl 2):s41–s46CrossRefPubMed
9.
Zurück zum Zitat Bade BC, Dela Cruz CS (2020) Lung cancer 2020: epidemiology, etiology, and prevention. Clin Chest Med 41:1–24CrossRefPubMed Bade BC, Dela Cruz CS (2020) Lung cancer 2020: epidemiology, etiology, and prevention. Clin Chest Med 41:1–24CrossRefPubMed
10.
Zurück zum Zitat Vinod SK, Hau E (2020) Radiotherapy treatment for lung cancer: current status and future directions. Respirology 25(Suppl 2):61–71CrossRefPubMed Vinod SK, Hau E (2020) Radiotherapy treatment for lung cancer: current status and future directions. Respirology 25(Suppl 2):61–71CrossRefPubMed
11.
Zurück zum Zitat Johnson GJ, Kilpatrick CC, Zaritsky E, Woodbury E, Boller M, Burton M, Asfaw T, Ratan BM (2021) Training the next generation of obstetrics and gynecology leaders, a multi-institutional needs assessment. J Surg Educ 78(6):1965–1972CrossRefPubMed Johnson GJ, Kilpatrick CC, Zaritsky E, Woodbury E, Boller M, Burton M, Asfaw T, Ratan BM (2021) Training the next generation of obstetrics and gynecology leaders, a multi-institutional needs assessment. J Surg Educ 78(6):1965–1972CrossRefPubMed
12.
Zurück zum Zitat Shi W, Tang Z, Chen L et al (2024) Radiotherapy in preclinical models of brain metastases: a review and recommendations for future studies. Int J Biol Sci 20(2):765–783CrossRefPubMedPubMedCentral Shi W, Tang Z, Chen L et al (2024) Radiotherapy in preclinical models of brain metastases: a review and recommendations for future studies. Int J Biol Sci 20(2):765–783CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Wang XS, Mendoza TR, Gao SZ, Cleeland CS (1996) The Chinese version of the brief pain inventory (BPI-C): its development and use in a study of cancer pain. Pain 67:407–416CrossRefPubMed Wang XS, Mendoza TR, Gao SZ, Cleeland CS (1996) The Chinese version of the brief pain inventory (BPI-C): its development and use in a study of cancer pain. Pain 67:407–416CrossRefPubMed
16.
Zurück zum Zitat Daut RL, Cleeland CS, Flanery RC (1983) Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain 17:197–210CrossRefPubMed Daut RL, Cleeland CS, Flanery RC (1983) Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain 17:197–210CrossRefPubMed
18.
Zurück zum Zitat Chie WC, Chang KJ, Huang CS, Kuo WH (2003) Quality of life of breast cancer patients in Taiwan: validation of the Taiwan Chinese version of the EORTC QLQ-C30 and EORTC QLQ-BR23. Psychooncology 12:729–735CrossRefPubMed Chie WC, Chang KJ, Huang CS, Kuo WH (2003) Quality of life of breast cancer patients in Taiwan: validation of the Taiwan Chinese version of the EORTC QLQ-C30 and EORTC QLQ-BR23. Psychooncology 12:729–735CrossRefPubMed
19.
20.
Zurück zum Zitat Liu K, Huang H, Zhang L, Huang Y, Sun S, Chen X et al (2021) Effects of a physician- and pharmacist-managed clinic on pain management in cancer patients in China. Basic Clin Pharmacol Toxicol 129(1):36–43CrossRefPubMed Liu K, Huang H, Zhang L, Huang Y, Sun S, Chen X et al (2021) Effects of a physician- and pharmacist-managed clinic on pain management in cancer patients in China. Basic Clin Pharmacol Toxicol 129(1):36–43CrossRefPubMed
21.
Zurück zum Zitat Greco MT, Roberto A, Corli O et al (2014) Quality of cancer pain management: an update of a systematic review of undertreatment of patients with cancer. J Clin Oncol 32:4149–4154CrossRefPubMed Greco MT, Roberto A, Corli O et al (2014) Quality of cancer pain management: an update of a systematic review of undertreatment of patients with cancer. J Clin Oncol 32:4149–4154CrossRefPubMed
25.
Zurück zum Zitat Bennett MI, Eisenberg E, Ahmedzai SH, Bhaskar A, O’Brien T, Mercadante S, KrčevskiŠkvarč N, Vissers K, Wirz S, Wells C, Morlion B (2019) Standards for the management of cancer-related pain across Europe—a position paper from the EFIC Task Force on Cancer Pain. Eur J Pain 23(4):660–668CrossRefPubMedPubMedCentral Bennett MI, Eisenberg E, Ahmedzai SH, Bhaskar A, O’Brien T, Mercadante S, KrčevskiŠkvarč N, Vissers K, Wirz S, Wells C, Morlion B (2019) Standards for the management of cancer-related pain across Europe—a position paper from the EFIC Task Force on Cancer Pain. Eur J Pain 23(4):660–668CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Bouabida K, Lebouché B, Pomey MP (2022) Telehealth and COVID-19 pandemic: an overview of the telehealth use, advantages, challenges, and opportunities during COVID-19 pandemic. Healthcare 10(11):2293CrossRefPubMedPubMedCentral Bouabida K, Lebouché B, Pomey MP (2022) Telehealth and COVID-19 pandemic: an overview of the telehealth use, advantages, challenges, and opportunities during COVID-19 pandemic. Healthcare 10(11):2293CrossRefPubMedPubMedCentral
Metadaten
Titel
The Impact of Standardized Training Resident on Pain Management in Patients with Advanced Lung Cancer
verfasst von
Hai-Zhen Yi
Wei Lv
Jin-Jing Chen
Zhan Lin
Publikationsdatum
27.10.2024
Verlag
Springer US
Erschienen in
Journal of Cancer Education
Print ISSN: 0885-8195
Elektronische ISSN: 1543-0154
DOI
https://doi.org/10.1007/s13187-024-02519-5

Neu im Fachgebiet Onkologie

CDK4/6-Inhibitoren bei Brustkrebs in die Zweitlinie aufschieben?

Ergebnisse einer Phase-III-Studie sprechen dafür, dass die Behandlung mit CDK4/6-Inhibitoren bei fortgeschrittenem HR-positivem, HER2-negativem Brustkrebs auch auf die Zweitlinie verschoben werden könnte, ohne die onkologischen Ergebnisse zu kompromittieren.

Cannabisextrakt verbessert Antiemese bei Chemotherapie

Sprechen Krebskranke auf die übliche Antiemese während einer Chemotherapie nicht ausreichend an, lohnt sich möglicherweise eine Behandlung mit Cannabisextrakt. In einer Phase-2/3-Studie ließ sich die antiemetische Response mit einem solchen Extrakt erheblich verbessern.

Veränderung der Brustdichte beeinflusst das Krebsrisiko

Die radiologische Dichte des Mammagewebes ist mit dem Risiko assoziiert, an Brustkrebs zu erkranken. Dabei wirken sich laut Ergebnissen einer Studie auch Dichteänderungen aus. Fünf Verlaufsmuster lassen sich dabei unterscheiden.

PMBCL mit CMR: Radiatio kann ohne Risiko weggelassen werden

Patienten mit primär mediastinalem B-Zell-Lymphom (PMBCL), die nach der Induktionstherapie eine komplette metabolische Remission (CMR) erreichen und keine konsolidierende Bestrahlung erhalten, müssen offenbar keine Überlebensnachteile fürchten.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.